Orgenesis Stock (NASDAQ:ORGS)


Chart

Previous Close

$1.18

52W Range

$0.87 - $10.80

50D Avg

$3.10

200D Avg

$5.40

Market Cap

$5.17M

Avg Vol (3M)

$34.65K

Beta

1.32

Div Yield

-

ORGS Company Profile


Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

146

IPO Date

Mar 13, 2012

Website

ORGS Performance


Latest Earnings Call Transcripts


Q2 22Aug 16, 22 | 5:22 PM
Q4 21Mar 30, 22 | 10:50 PM
Q1 21May 10, 21 | 11:09 AM

Peer Comparison


TickerCompany
TFFPTFF Pharmaceuticals, Inc.
NRBONeuroBo Pharmaceuticals, Inc.
ADAGAdagene Inc.
ACHLAchilles Therapeutics plc